Recently [1]Winkler et al. [2] reported that total cholesterol, LDL-C and small, dense LDL (sdLDL) were significantly reduced with ezetimibe 10 mg (E10), simvastatin 20 mg (S20) and the combination of E10 ⁄ S20 in patients with type 2 diabetes and a preponderance of sdLDL. The further decrease of sdLDL by adding ezetimibe to simvastatin was not significant. Florentin et al. [3] showed that S10 plus E10 is similarly effective to S40 in improving sdLDL and LDL particle size in patients with primary hypercholesterolaemia. In the study of Berneis et al. [4], healthy men were treated with Recent clinical [42] studies have largely confirmed the association between increased FGF21 levels and the presence of nonalcoholic fatty liver disease (NAFLD). In addition, the evidence that FGF21 chiefly mirrors the extent of hepatic steatosis has reinforced. In this regard, Li et al. [43] reported that serum